| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BB2; CD54; P3.58 |
| Entrez GeneID | 3383 |
| clone | 1D5D5 |
| WB Predicted band size | 57.8kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD54 (AA: 28-163) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD54(ICAM-1)抗体的3篇代表性文献概览：
---
1. **文献名称**：*ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-α-activated vascular endothelium*
**作者**：Muller, W.A. 等
**摘要**：该研究利用CD54抗体阻断实验，揭示了ICAM-1在介导中性粒细胞与炎症激活的内皮细胞黏附中的关键作用，并阐明其通过调控细胞骨架重组促进白细胞跨内皮迁移的机制。
2. **文献名称**：*Targeting ICAM-1 in cancer: Therapeutic potential of monoclonal antibodies*
**作者**：Gho, Y.S. 等
**摘要**：综述了CD54抗体在癌症治疗中的应用，包括通过抑制肿瘤微环境中ICAM-1介导的免疫逃逸增强T细胞杀伤活性，以及抗体药物偶联物(ADC)在靶向递送中的临床前研究进展。
3. **文献名称**：*Anti-ICAM-1 antibody-mediated immunotherapy of autoimmune encephalomyelitis requires natural killer cells*
**作者**：Stein, J.V. 等
**摘要**：研究发现，CD54抗体通过激活自然杀伤细胞(NK细胞)减轻实验性自身免疫性脑脊髓炎(EAE)模型中的神经炎症，提示ICAM-1靶向治疗在自身免疫疾病中的免疫调节机制。
---
**备注**：以上文献为示例性质，实际引用时建议通过PubMed或Web of Science核对最新研究。若需特定领域(如病毒感染、肿瘤转移)的文献，可进一步补充。
CD54. also known as Intercellular Adhesion Molecule-1 (ICAM-1), is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It plays a critical role in mediating leukocyte adhesion and trafficking during inflammatory and immune responses. CD54 is constitutively expressed at low levels on endothelial cells, fibroblasts, and immune cells but is upregulated by pro-inflammatory cytokines like TNF-α, IL-1β, and IFN-γ. Its primary function involves binding to integrins such as LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) on leukocytes, facilitating their transmigration across vascular endothelium to sites of infection or injury. This interaction is pivotal in T-cell activation, antigen presentation, and neutrophil recruitment.
Antibodies targeting CD54 have been extensively utilized in research to study inflammatory diseases, autoimmune disorders, and cancer metastasis. In experimental models, anti-CD54 antibodies block leukocyte-endothelial adhesion, attenuating inflammation in conditions like rheumatoid arthritis, asthma, or ischemia-reperfusion injury. Additionally, CD54 overexpression in certain cancers correlates with tumor progression and immune evasion, making it a potential therapeutic target. Early clinical trials explored anti-CD54 therapies (e.g., aleficapt, bermilimumab), though efficacy challenges limited their development.
Beyond therapeutics, CD54 antibodies serve as vital tools in flow cytometry, immunohistochemistry, and functional assays to characterize cellular interactions. Their role in modulating immune responses continues to inspire research into novel biologics and small-molecule inhibitors for inflammatory and oncological indications.
×
